1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?

Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?

  • November 2014
  • ID: 3509556
  • Format: PDF
  • By Firstword Pharma

Summary






Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis treatment Lemtrada was green-lighted for launch in the US earlier this month.


The product featured notably during Sanofi's investor day last week and continues to intrigue, given the combination of its impressive efficacy and notable side-effect profile.


While EU regulators were less cautious in their appraisal of Lemtrada (approving for use in first-line patients if physicians see fit), the FDA approved a label that limits use to the third-line setting.


Patients who see their MS progress beyond two lines of therapy still represent a significant share of the relapsing market, equal to around 50 percent of all patients, noted Sanofi management last week (ViewPoints: Sanofi's Lemtrada flies the flag for patient power; can it carve a niche in the US multiple sclerosis market?).


The French company argues that uptake among European physicians is encouraging (a trend supported by a pre-launch Physician Views poll run by FirstWord last year; Physician Views Poll Results – Sanofi's new multiple sclerosis treatment Lemtrada to be used more widely than expected?), with a lack of significant revenue to date illustrative of the protracted reimbursement processes that are typical of the region. Consensus forecasts sourced from Bloomberg indicate global sales in 2018 of around $365 million.








With these factors in mind, coupled with reportedly strong US patient advocacy support to influence the FDA's assessment of Sanofi's drug, we are polling US based neurologists to ascertain how they expect to prescribe Lemtrada. Specifically we are asking them...


To what percentage of patients with relapsing forms of MS would you expect to prescribe Lemtrada 12 months post-launch?
Based on your knowledge of the product, in what line of therapy (irrespective of labelling for the drug) do you think use of Lemtrada is best suited?
What barrier to usage do you expect Lemtrada's specified use in third-line patients will provide?
Would you consider prescribing Lemtrada in an off-label (i.e. earlier than third line) capacity?
At peak, to what percentage of relapsing MS patients would you expect to prescribe Lemtrada?


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Hepatic Encephalopathy- Epidemiology Forecast-2028

Hepatic Encephalopathy- Epidemiology Forecast-2028

  • $ 3250
  • September 2019

‘Hepatic Encephalopathy- Epidemiology Forecast-2028’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology trends of Hepatic Encephalopathy in the United ...

Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028

Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028

  • $ 3495
  • August 2019

Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028SummarySpinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha ...

Orthotic Devices - Medical Devices Pipeline Assessment, 2019

Orthotic Devices - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • October 2019

Orthotic Devices - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Orthotic Devices - Medical Devices Pipeline Assessment, 2019" provides an overview of Orthotic Devices ...


ref:plp2014

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on